New acne cream shows promise in small safety trial
NCT ID NCT06671834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
Pfizer completed a Phase 1 study testing a new topical drug called PF-07905428 for acne. The study included 52 healthy volunteers and people with moderate to severe acne, who applied the drug daily for 14 or 28 days. The main goal was to check safety and side effects, not to see if it works. This early research helps decide if larger studies should go forward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07905428 (topical solution)
- What this could lead to
- If it works, this could point toward a new topical treatment for moderate to severe acne.
- What could go wrong
- This is a very early Phase 1 study with only 52 participants, focused on safety. It is too small to prove effectiveness, and the drug may not work or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentle cream outperform harsh acne drugs?
- Can acne drug harm the eyes? new study investigates
- A new serum aims to clear acne and boost skin confidence
- Head-to-Head: which acne cream works better for clear skin?
- Acne Treatment's Oil-Reducing power put to the test
- AI writes acne guide, students score same as human version